Nuvalent, Inc. Nuvalent, Inc.

Nuvalent, Inc.

NUVL

Classement en actions #2113
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to... Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Prix de l'action
$123.96
Dernière synchronisation: 2026-07-21
Capitalisation boursière
$9.75B
Changement (1 jour)
0.00%
Changement (1 an)
27.56%
Pays
US
Échange Nuvalent, Inc. (NUVL)

Catégorie

Healthcare
Historique des divisions d’actions pour Nuvalent, Inc. (NUVL)
L’action Nuvalent, Inc. (symbole : NUVL) a subi un total de 0 divisions.
La division la plus récente a eu lieu le Oct 21, 2026.
Une action NUVL achetée avant le Oct 21, 2026 équivaudrait aujourd’hui à 0 actions NUVL.
Liste des divisions d’actions
Année Division Multiplicateur Multiplicateur cumulatif
Pas assez de données pour les dates fournies.
Divisions d’actions d’entreprises similaires ou concurrentes
Entreprise Nombre de divisions d’actions Multiplicateur cumulatif Pays
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL